San Francisco, United States
Genotic, founded in 2021, is pioneering advancements at the intersection of AI and Biotechnology. Headquartered in the United States, it aims to revolutionize the antibody market with its succinctly stated motto: "Design, Production, and Delivery of Antibodies – Reimagined by AI."
The core of Genotic's innovation lies in its use of artificial intelligence to facilitate the rapid design and production of customized antibodies. The company’s strategy emphasizes a fully computational process that eliminates the need for animals. This ensures not only a more ethical approach but also guarantees high-quality antibodies delivered within weeks, significantly shortening the traditional timeline from years.
Currently, there is no record of Genotic's last investment or its investors, indicating potential opportunities for first-mover advantages in capital partnerships. Their unique proposition positions them well in the biotech landscape, addressing an industry demand for speed and innovation.
